Cargando…
Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist
Autores principales: | Zhang, Manchao, Luo, Zhenghua, Liu, Hongpeng, Croce, Carlo M., Burke, Terrence R., Bottaro, Donald P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981872/ https://www.ncbi.nlm.nih.gov/pubmed/24172825 http://dx.doi.org/10.1038/leu.2013.323 |
Ejemplares similares
-
Development of Grb2 SH2 Domain Signaling Antagonists: A Potential New Class of Antiproliferative Agents
por: Burke , Terrence R.
Publicado: (2006) -
Targeting the Interaction between the SH3 Domain of Grb2 and Gab2
por: Malagrinò, Francesca, et al.
Publicado: (2020) -
NHD2-15, a novel antagonist of Growth Factor Receptor-Bound Protein-2 (GRB2), inhibits leukemic proliferation
por: Lewis, Tina R., et al.
Publicado: (2020) -
GRB2 dimerization mediated by SH2 domain-swapping is critical for T cell signaling and cytokine production
por: Sandouk, Aline, et al.
Publicado: (2023) -
Grb2 carboxyl-terminal SH3 domain can bivalently associate with two ligands, in an SH3 dependent manner
por: Arya, Richa, et al.
Publicado: (2017)